Drug intelligence / Profile preview

RP916

Development stage: Preclinical
Lead developer: Risen Medical Technology
Modality: Small Molecules

Overview

RP916 is a small-molecule antiviral agent being developed by Risen Shanghai Medical Technology for the treatment of mpox virus infection. It functions as an inhibitor of the viral DNA polymerase, an essential enzyme required for the replication of the mpox virus genome. By targeting this polymerase, RP916 aims to block viral replication and reduce viral load in infected patients. The drug is being developed in collaboration with the Shanghai Center for Infection and Immunity Technology Innovation and is currently in the IND-enabling stage of development.

Targets

DNA polymerase family

Beyond the preview

Go deeper on RP916.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RP916.

Explore the full profile